Article: Publication No. WO/2009/088786 Published on July 16, Assigned to Nanocor Therapeutics for Ribonucleic Acid (American, German Inventors)

GENEVA, July 20 -- Roger J. Hajjar, the U.S., and Wolfgang Ch Poller and Henry Fechner, both of Germany, have developed a targeted ribonucleic acid for the treatment of heart failure.

The patent has been assigned to Nanocor Therapeutics Inc., Chapel Hill, N.C.

According to an abstract posted by the World Intellectual Property Organization, in the invention relates to the "targeted ribonucleic acidi for the treatment of heart failure by modulating defective cardiac carbonic anhydrase 2 positive homeostasis via ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!